Top 50 Companies in the Global Cancer Diagnostics Market: Statistics Report Till 2035
RELEASE DATE: Aug 2025 Author: Spherical InsightsRequest Free Sample Speak to Analyst
Description
According to a research report published by Spherical Insights & Consulting, The Global Cancer Diagnostics Market Size is projected to Grow from USD 151.34 Billion in 2024 to USD 367.15 Billion by 2035, at a CAGR of 8.39% during the forecast period 2025–2035. Across the globe, cancer has a major social impact. It is one of the leading causes of death globally, and its incidence is increasing in both developed and emerging markets. The alarming increase in cancer incidence prompts medical professionals to reevaluate their treatment goals and prioritize prevention.
Introduction
The process of finding proteins, biomarkers, and other signs that help identify a malignant tumor is known as cancer diagnostics. To schedule and evaluate treatment results, monitor the course of a condition, and confirm or rule out the presence of illness, diagnostic testing is utilized. Imaging, tumor biopsy, endoscopic inspection, genetic testing, laboratory testing (including tumor marker testing), and surgery are all potential methods for diagnosing cancer. Cancer diagnostics is the process of finding a patient's presence of a malignant tumor by identifying a variety of proteins, biomarkers, and specific symptoms. Certain proteins and biomarkers that are prevalent in cancer diseases can be found, which helps with the diagnosis procedure.
Navigate Future Markets with Confidence: Insights from Spherical Insights LLP
The insights presented in this blog are derived from comprehensive market research conducted by Spherical Insights LLP, a trusted advisory partner to leading global enterprises. Backed by in-depth data analysis, expert forecasting, and industry-specific intelligence, our reports empower decision-makers to identify strategic growth opportunities in fast-evolving sectors. Clients seeking detailed market segmentation, competitive landscapes, regional outlooks, and future investment trends will find immense value in the full report. By leveraging our research, businesses can make informed decisions, gain a competitive edge, and stay ahead in the transition toward sustainable and profitable solutions.
Unlock exclusive market insights-Download the Brochure now and dive deeper into the future of the Cancer Diagnostics Market.
Cancer Diagnostics Market Size & Statistics
- The Market Size for Cancer Diagnostics Was Estimated to be worth USD 151.34 Billion in 2024.
- The Market is Going to Expand at a CAGR of 8.39% between 2025 and 2035.
- The Global Cancer Diagnostics Market Size is anticipated to reach USD 367.15 Billion by 2035.
- North America is expected to generate the highest demand during the forecast period in the Cancer Diagnostics Market
- Asia Pacific is expected to grow the fastest during the forecast period in the Cancer Diagnostics Market.
Regional growth and demand
Asia Pacific is expected to grow the fastest during the forecast period in the cancer diagnostics market. Asia Pacific is expected to grow rapidly throughout the projection period due to a number of factors, including rising cancer rates, a sizable elderly population, rising healthcare costs, the adoption of cutting-edge technologies, and government initiatives. Promoting awareness of cancer and the significance of treatment options is the main goal of the Asian Government. Research and development expenditures made by the government also encourage the creation of new, cutting-edge diagnostic tools and therapeutic alternatives. In Asia, medical tourism is expanding at an astounding rate.
North America is expected to generate the highest demand during the forecast period in the cancer diagnostics market. A strong medical environment in the fight against cancer is being built in North America thanks to grants from government healthcare organizations and targeted oncology research efforts for the development of early tumor detection techniques. This has allowed North America to hold the top spot in the global market for cancer diagnostics. Further contributing to the market expansion have been the growing number of biotechnology and medical device companies, the expansion of funding for R&D projects, and the widespread use of innovative technologies in this area.
Top 10 trends in the Cancer Diagnostics Market
- Artificial intelligence integration in diagnostic tools
- Liquid biopsy and non-invasive testing methods
- Growth of next-generation sequencing (NGS) and genomic profiling
- Expansion of companion diagnostics and personalized medicine
- Advanced imaging technologies and digital pathology
- Wider implementation of laboratory developed tests (LDTs)
- Biomarker-based diagnostics and multiplex assays
- Expansion of point-of-care diagnostic solutions
- Increased government funding and screening programs
- Collaborative industry partnerships and open-platform innovation
1. Artificial intelligence integration in diagnostic tools
AI is reshaping cancer diagnostics by enhancing pattern recognition, automating routine tasks, and supporting clinical decision-making. Tools powered by AI improve the accuracy, speed, and consistency of image and biomarker analysis, enabling early and precise cancer detection. Clinical practices are increasingly adopting AI to predict cancer recurrence risk and optimize treatment plans, reflecting a transformative market shift.
2. Liquid biopsy and non-invasive testing methods
Non-invasive diagnostics such as liquid biopsy test blood or other body fluids for circulating tumor DNA, cells, or proteins. These tools are revolutionizing early cancer detection, monitoring tumor progression, and guiding therapy choices, offering a less invasive, quicker, and often more comprehensive alternative to traditional biopsies.
3. Growth of next-generation sequencing (NGS) and genomic profiling
NGS technologies are enabling comprehensive genetic profiling of tumors, identifying actionable mutations and informing targeted therapies. This trend supports the rise of precision oncology, where treatments are tailored to each patient’s genetic makeup, further fueling demand for sophisticated genomic diagnostics.
4. Expansion of companion diagnostics and personalized medicine
Increasingly, diagnostic tests are developed alongside specific targeted therapies (companion diagnostics) to determine which patients are most likely to benefit. This has accelerated the rise of personalized medicine in oncology, linking biomarker detection with individualized treatment strategies to improve outcomes.
5. Advanced imaging technologies and digital pathology
Improvements in imaging modalities (MRI, PET, CT) and the digitization of pathology slides have increased the accuracy and accessibility of cancer diagnostics. Digital pathology, especially when integrated with AI, allows for faster, more reliable analysis and remote consultations, expanding diagnostic access and efficiency.
Empower your strategic planning:
Stay informed with the latest industry insights and market trends to identify new opportunities and drive growth in the cancer diagnostics market. To explore more in-depth trends, insights, and forecasts, please refer to our detailed report.
Top 25 Companies Leading the Cancer Diagnostics Market
- F. Hoffmann-La Roche Ltd.
- Illumina, Inc.
- Guardant Health
- Bio-Rad Laboratories
- Abbott Laboratories
- Qiagen
- Agilent Technologies
- Thermo Fisher Scientific
- Siemens Healthineers
- GE Healthcare
- BD (Becton, Dickinson and Company)
- PerkinElmer
- Myriad Genetics
- Sysmex Corporation
- Danaher Corporation
- Exact Sciences
- Nanostring Technologies
- Biocept
- Beckman Coulter
- Hologic
- Menarini Silicon Biosystems
- Biocartis
- Invitae
- Genomic Health
- Foundation Medicine
1. F. Hoffmann-La Roche Ltd.
Headquarters: Basel, Switzerland
F. Hoffmann-La Roche Ltd., commonly known as Roche, is a global leader in cancer diagnostics, acclaimed for its groundbreaking work in precision oncology and molecular testing. Based in Basel, Switzerland, Roche integrates advanced solutions such as next-generation sequencing (NGS), digital pathology, and liquid biopsy through its subsidiaries and collaborations. Roche’s AVENIO ctDNA assays exemplify innovation in non-invasive cancer detection and monitoring. The company’s strong regulatory expertise, extensive global network, and deep R&D capabilities support rapid advancements in early detection and personalized medicine. Roche continues to be at the forefront of the cancer diagnostics market, focusing on accessible, high-impact technologies that improve outcomes worldwide.
2. Illumina, Inc.
Headquarters: San Diego, California, USA
Illumina, Inc. is a world-renowned genomics technology company anchoring the cancer diagnostics market from San Diego, California. Illumina’s next-generation sequencing (NGS) platforms enable comprehensive genetic profiling in oncology, fueling rapid growth in precision medicine. As a foundational partner to many liquid biopsy and genomics-driven diagnostic firms, Illumina drives integration of high-throughput, scalable, and affordable sequencing solutions. The company’s instruments and reagents are central to identifying actionable mutations and guiding targeted therapies for cancer. Illumina’s innovation continually advances cancer detection, monitoring, and treatment selection, placing it firmly among the sector’s top innovators.
3. Guardant Health
Headquarters: Redwood City, California, USA
Guardant Health is a trailblazer in precision oncology, specializing in advanced liquid biopsy diagnostics from its base in Redwood City, California. The company is acclaimed for products like Guardant360®, which offers comprehensive genomic profiling of solid tumors with a simple blood test. Guardant’s digital sequencing technology enables detection of circulating tumor DNA (ctDNA) for early cancer identification, real-time monitoring, and recurrence risk prediction. The firm’s collaborative approach with clinicians and biopharma drives adoption of non-invasive diagnostics, supporting improved patient outcomes and personalized treatment strategies. Guardant Health’s innovations underscore major trends in non-invasive, data-driven cancer care.
4. Bio-Rad Laboratories
Headquarters: Hercules, California, USA
Bio-Rad Laboratories is a global leader in life science research and clinical diagnostics, headquartered in Hercules, California. Within cancer diagnostics, Bio-Rad is renowned for its Droplet Digital PCR (ddPCR) technology, a benchmark in precise detection of rare genetic mutations in circulating tumor DNA (ctDNA). This platform is widely used in oncology research, aiding in early detection and disease monitoring. Bio-Rad’s robust portfolio spans instruments, consumables, and software, offering scientists and clinicians reliable, high-sensitivity molecular tools. The company’s focus on innovation and quality supports personalized medicine and shapes ongoing advancements in liquid biopsy and cancer diagnostic markets.
5. Abbott Laboratories
Headquarters: Abbott Park, Illinois, USA
Abbott Laboratories, based in Abbott Park, Illinois, stands as a dominant force in the cancer diagnostics market, emphasizing innovation in immunoassays, molecular diagnostics, and companion diagnostics. Abbott’s portfolio includes leading cancer screening tests for markers such as PSA (prostate cancer), CEA (colorectal cancer), and advanced real-time PCR systems. Their solutions are widely adopted in hospitals and clinical laboratories globally, reflecting strong reliability and sensitivity in cancer detection. Abbott continually advances automation and connectivity in diagnostic workflows, facilitating rapid and accurate results for clinicians and patients. The company’s commitment to quality and technological advancement cements its influence in early cancer detection and monitoring
Are you ready to discover more about the cancer diagnostics market?
The report provides an in-depth analysis of the leading companies operating in the global cancer diagnostics market. It includes a comparative assessment based on their product portfolios, business overviews, geographical footprint, strategic initiatives, market segment share, and SWOT analysis. Each company is profiled using a standardized format that includes:
Company Profiles
- F. Hoffmann-La Roche Ltd.
- Business Overview
- Company Snapshot
- Products Overview
- Company Market Share Analysis
- Company Coverage Portfolio
- Financial Analysis
- Recent Developments
- Merger and Acquisitions
- SWOT Analysis
- Illumina, Inc.
- Guardant Health
- Bio-Rad Laboratories
- Abbott Laboratories
- Qiagen
- Agilent Technologies
- Thermo Fisher Scientific
- Siemens Healthineers
- Others.
Conclusion
The cancer diagnostics market is evolving rapidly with breakthroughs in AI, liquid biopsy, and next-generation sequencing driving early and precise cancer detection. Leading companies are advancing personalized medicine through companion diagnostics and integrated genomic profiling, improving treatment outcomes. Innovations in digital pathology and non-invasive testing are increasing accessibility and efficiency in clinical settings worldwide. Growing government support and collaborations are accelerating the adoption of advanced diagnostic solutions. Overall, the market is poised for significant growth, transforming cancer care with innovative technologies and patient-centric approaches.
About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.
Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.
CONTACT US:
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com
Contact Us: https://www.sphericalinsights.com/contact-us
Need help to buy this report?